Baker Bros. Advisors Reduces $11M in Immatics N.V. ($IMTX)
Key Points
- Baker Bros. Advisors changed its Immatics N.V. ($IMTX) stake by 9.7% last quarter, cutting to 10,916,693 shares worth $102.40 million.
- Wall Street's consensus rating on $IMTX is Strong Buy and an average price target of $18.77.
- $IMTX last traded around $9.38.
Baker Bros. Advisors trimmed its position in Immatics N.V. ($IMTX) by 9.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,916,693 shares of Immatics N.V. after selling 1,177,401 shares during the quarter. Baker Bros. Advisors's holdings in Immatics N.V. were worth $102.40 million as of its most recent filing.
Immatics N.V. ($IMTX) Stock
Immatics N.V. Earnings
Analysts Set New Price Targets
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.